Supplementary Tables 1-3. from SMARCA4/BRG1 Is a Novel Prognostic Biomarker Predictive of Cisplatin-Based Chemotherapy Outcomes in Resected Non–Small Cell Lung Cancer

Abstract

Supplementary Table 1. Univariate analysis of SMARCA4 expression in the Director's Challenge Study. Supplementary Table 2. Log-rank analysis of SMARCA4 expression for observation vs adjuvant cisplatin/vinorelbine in NSCLC within the JBR.10 trial. Supplementary Table 3. Univariate analysis of SMARCA4 expression in the JBR.10 trial.